The central nervous system-focused drug developer has raised approximately $124m so far from investors including 3M.
Impel NeuroPharma, a US-based central nervous system drug developer backed by manufacturing group 3M, has filed to raise $75m in an initial public offering on the Nasdaq Global Market. Founded in 2008, Impel is developing therapies for patients with central nervous system disorders. It has also developed a medical device that delivers medicine to the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.